A new scaleable method for the purification of botulinum neurotoxin type E.

Cloning, Expression and Purification of Clostridium botulinum Neurotoxin Type E Binding Domain

Expression and Purification of Neurotoxin-Associated Protein HA-33/A from Clostridium botulinum and Evaluation of Its Antigenicity

Background: Botulinum neurotoxin (BoNT) complexes consist of neurotoxin and neurotoxin-associated proteins. Hemagglutinin-33 (HA-33) is a member of BoNT type A (BoNT/A) complex. Considering the protective role of HA-33 in preservation of BoNT/A in gastrointestinal harsh conditions and also its adjuvant role, recombinant production of this protein is favorable. Thus in this study, HA-33 was expr...

The effect of pH on recombinant C-terminal domain of Botulinum Neurotoxin type E (rBoNT/E-HCC)

Recombinant proteins are tending to be the most favorable vaccine-candidates against botulism. Recombinant Carboxy-terminal of botulinum neurotoxin serotype E (rBoNT/E-HCC) has been introduced as an efficient vaccine against botulism type E. In this report, we made an effort to investigate the effect of different pH on protein structure to assess if rBoNT/E-HCC could be used as a vaccine for or...

Immunogenic and Protective Potentials of Recombinant Receptor Binding Domain and a C-Terminal Fragment of Clostridium botulinum Neurotoxin Type E

Clostridium Botulinum Type E neurotoxin heavy chain consists of two domains: the translocation domain asthe N-terminal half and the binding domain as the Cterminal half (Hc). One effective way to neutralize botulinum neurotoxin is to inhibit binding of this toxin to neuromuscular synapses with antibodies against binding domain. Two synthetic genes, coding for Hc (the full length binding d...

بررسی ایمنی‌زایی نانوذرات کیتوسان حاوی پروتئین نوترکیب ناحیه اتصال‌دهنده نوروتوکسین بوتولینوم تیپ E در موش

Abstract Background and purpose: Clostridium botulinum neurotoxins are the most potent toxins that cause the life-threatening botulism syndrome in humans and animals. Researches have shown that the binding domain of the botulinum neurotoxin type E has a high immunogenicity effect that could be used as an efficient recombinant vaccine. The recombinant vaccines are not potent enough to stimulate...